Latest news and press releases about Molecular Partners AG (MOLN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema.
Price
| Price | $3.92 |
| Market Cap | $147M |
| Exchange | NASDAQ |
| Country | CH |
Valuation Ratios
| Price / Book | 2.08 |
| EV / EBITDA | -1.34 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -67.67% |
| Return on Invested Capital | -76.91% |
| Return on Assets | -67.68% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CRBP · CRDF · ELTX · MIST · NKTX
Explore sector: Healthcare · Biotechnology
More sections of MOLN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks